Passage Bio, Inc.
PASGAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| TD Cowen | downgrade | Buy →Hold | Apr 21, 2026 |
| Wedbush | downgrade | Outperform →Neutral | Apr 21, 2026 |
| Oppenheimer | maintain | Outperform | Apr 21, 2026 |
| Chardan Capital | downgrade | Buy →Neutral | Apr 21, 2026 |
| Canaccord Genuity | maintain | Buy | Mar 4, 2026 |
| Chardan Capital | maintain | Buy | Nov 12, 2025 |
| Canaccord Genuity | maintain | Buy | Aug 14, 2025 |
| Guggenheim | maintain | Buy | Aug 14, 2025 |
| Wedbush | maintain | Outperform | Aug 13, 2025 |
| Chardan Capital | maintain | Buy | Jun 24, 2025 |
| Chardan Capital | maintain | Buy | Mar 4, 2025 |
| Chardan Capital | maintain | Buy | Nov 14, 2024 |
| Canaccord Genuity | maintain | Buy | Nov 14, 2024 |
| Canaccord Genuity | maintain | Buy | Sep 17, 2024 |
| Canaccord Genuity | maintain | Buy | May 15, 2024 |
| Canaccord Genuity | maintain | Buy | Mar 5, 2024 |
| Raymond James | maintain | Outperform | Nov 14, 2023 |
| Chardan Capital | maintain | Buy | Aug 8, 2023 |
| Raymond James | maintain | Outperform | May 12, 2023 |
| Chardan Capital | maintain | Buy | Dec 15, 2022 |
| Guggenheim | maintain | Buy | Nov 11, 2022 |
| Citigroup | maintain | Buy | Nov 11, 2022 |
| Canaccord Genuity | maintain | Buy | Nov 8, 2022 |
| Raymond James | maintain | Outperform | May 17, 2022 |
| Citigroup | maintain | Buy | May 17, 2022 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 10, 2026 | $-2.44 | $-2.27 | — | — |
| May 12, 2026 | $-2.36 | $-2.15 | — | — |
| Mar 3, 2026 | $-4.08 | $-2.19 | — | — |
| Nov 10, 2025 | $-2.44 | $-2.76 | — | — |
| Aug 12, 2025 | $-2.96 | $-4.00 | — | — |
| May 13, 2025 | $-5.00 | $-4.60 | — | — |
| Mar 4, 2025 | $-4.00 | $-0.23 | — | — |
| Nov 13, 2024 | $-6.20 | $-4.60 | — | $1.7M |
News
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report.
MERGER VOTE ALERT: The M&A Class Action Firm Is Investigating the Merger Vote -- UTZ, SAFT, PASG and FNWDPR NewswireNEW YORK, Oct. 25, 2026NEW YORK, Oct. 25, 20
Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Passage Bio, Inc. (NASDAQ: PASG) and Remix Therapeutics, Inc. Upon closing of the
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Passage Bio, Inc. (NASDAQ: PASG) and Remix Therapeutics, Inc. Upon closing of the proposed transaction, Passage Bio shareholders are expected to own approximately 7% of the combined company. Halper Sadeh encourages Passage Bio shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating:
Shares of Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) have earned a consensus rating of "Hold" from the nine ratings firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and two have issued a buy recommendation on the
Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) shares traded down 2.4% during mid-day trading on Friday. The stock traded as low as $3.61 and last traded at $3.69. Approximately 12,111 shares were traded during trading, a decline of 42% from the average session volume of 21,058 shares. The stock had previously closed at $3.78.
Shares of Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) have been assigned an average rating of "Hold" from the nine research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and two have issued a buy